WO1994023646A1 - Stabilisation de colorants sensibles a la tension - Google Patents
Stabilisation de colorants sensibles a la tension Download PDFInfo
- Publication number
- WO1994023646A1 WO1994023646A1 PCT/US1994/004267 US9404267W WO9423646A1 WO 1994023646 A1 WO1994023646 A1 WO 1994023646A1 US 9404267 W US9404267 W US 9404267W WO 9423646 A1 WO9423646 A1 WO 9423646A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dye
- composition
- indocyanine green
- antioxidant
- blue
- Prior art date
Links
- 239000000975 dye Substances 0.000 title abstract description 34
- 230000006641 stabilisation Effects 0.000 title description 3
- 238000011105 stabilization Methods 0.000 title description 3
- 239000000203 mixture Substances 0.000 claims abstract description 52
- 238000003860 storage Methods 0.000 claims abstract description 19
- 239000007864 aqueous solution Substances 0.000 claims abstract description 18
- 239000000243 solution Substances 0.000 claims description 70
- 229960004657 indocyanine green Drugs 0.000 claims description 49
- MOFVSTNWEDAEEK-UHFFFAOYSA-M indocyanine green Chemical compound [Na+].[O-]S(=O)(=O)CCCCN1C2=CC=C3C=CC=CC3=C2C(C)(C)C1=CC=CC=CC=CC1=[N+](CCCCS([O-])(=O)=O)C2=CC=C(C=CC=C3)C3=C2C1(C)C MOFVSTNWEDAEEK-UHFFFAOYSA-M 0.000 claims description 49
- 238000000354 decomposition reaction Methods 0.000 claims description 28
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 25
- 239000003963 antioxidant agent Substances 0.000 claims description 14
- 235000006708 antioxidants Nutrition 0.000 claims description 14
- 239000003153 chemical reaction reagent Substances 0.000 claims description 14
- 229940072107 ascorbate Drugs 0.000 claims description 13
- 235000010323 ascorbic acid Nutrition 0.000 claims description 13
- 239000011668 ascorbic acid Substances 0.000 claims description 13
- 239000004094 surface-active agent Substances 0.000 claims description 13
- 230000003078 antioxidant effect Effects 0.000 claims description 12
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 12
- 238000003384 imaging method Methods 0.000 claims description 12
- IQFVPQOLBLOTPF-HKXUKFGYSA-L congo red Chemical compound [Na+].[Na+].C1=CC=CC2=C(N)C(/N=N/C3=CC=C(C=C3)C3=CC=C(C=C3)/N=N/C3=C(C4=CC=CC=C4C(=C3)S([O-])(=O)=O)N)=CC(S([O-])(=O)=O)=C21 IQFVPQOLBLOTPF-HKXUKFGYSA-L 0.000 claims description 8
- 239000011734 sodium Substances 0.000 claims description 8
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 claims description 7
- 229960003699 evans blue Drugs 0.000 claims description 7
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims description 7
- KHLVKKOJDHCJMG-QDBORUFSSA-L indigo carmine Chemical compound [Na+].[Na+].N/1C2=CC=C(S([O-])(=O)=O)C=C2C(=O)C\1=C1/NC2=CC=C(S(=O)(=O)[O-])C=C2C1=O KHLVKKOJDHCJMG-QDBORUFSSA-L 0.000 claims description 7
- 229960003988 indigo carmine Drugs 0.000 claims description 7
- 235000012738 indigotine Nutrition 0.000 claims description 7
- 239000004179 indigotine Substances 0.000 claims description 7
- 230000002401 inhibitory effect Effects 0.000 claims description 7
- 229920000136 polysorbate Polymers 0.000 claims description 7
- 108010024636 Glutathione Proteins 0.000 claims description 6
- 229960003180 glutathione Drugs 0.000 claims description 6
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 claims description 5
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 3
- 229940020947 fluorescein sodium Drugs 0.000 claims description 3
- 229920001983 poloxamer Polymers 0.000 claims description 3
- 229940068965 polysorbates Drugs 0.000 claims description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 4
- SJEYSFABYSGQBG-UHFFFAOYSA-M Patent blue Chemical compound [Na+].C1=CC(N(CC)CC)=CC=C1C(C=1C(=CC(=CC=1)S([O-])(=O)=O)S([O-])(=O)=O)=C1C=CC(=[N+](CC)CC)C=C1 SJEYSFABYSGQBG-UHFFFAOYSA-M 0.000 claims 4
- 125000003289 ascorbyl group Chemical group [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 claims 4
- 229910052708 sodium Inorganic materials 0.000 claims 4
- 229950008882 polysorbate Drugs 0.000 claims 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 239000005864 Sulphur Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 abstract description 6
- 238000012634 optical imaging Methods 0.000 abstract description 3
- 239000002872 contrast media Substances 0.000 abstract description 2
- 238000002835 absorbance Methods 0.000 description 24
- 230000007423 decrease Effects 0.000 description 9
- 230000003247 decreasing effect Effects 0.000 description 9
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 239000000872 buffer Substances 0.000 description 7
- 239000008363 phosphate buffer Substances 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 229910001868 water Inorganic materials 0.000 description 5
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 235000010378 sodium ascorbate Nutrition 0.000 description 4
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 4
- 229960005055 sodium ascorbate Drugs 0.000 description 4
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 229910052786 argon Inorganic materials 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- DZVCFNFOPIZQKX-LTHRDKTGSA-M merocyanine Chemical compound [Na+].O=C1N(CCCC)C(=O)N(CCCC)C(=O)C1=C\C=C\C=C/1N(CCCS([O-])(=O)=O)C2=CC=CC=C2O\1 DZVCFNFOPIZQKX-LTHRDKTGSA-M 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 3
- PMNLUUOXGOOLSP-UHFFFAOYSA-N 2-mercaptopropanoic acid Chemical compound CC(S)C(O)=O PMNLUUOXGOOLSP-UHFFFAOYSA-N 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 229940001584 sodium metabisulfite Drugs 0.000 description 2
- 235000010262 sodium metabisulphite Nutrition 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000013008 thixotropic agent Substances 0.000 description 2
- 238000002371 ultraviolet--visible spectrum Methods 0.000 description 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- DYIOSHGVFJTOAR-JGWLITMVSA-N (2r,3r,4s,5r)-6-sulfanylhexane-1,2,3,4,5-pentol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)CS DYIOSHGVFJTOAR-JGWLITMVSA-N 0.000 description 1
- INGWEZCOABYORO-UHFFFAOYSA-N 2-(furan-2-yl)-7-methyl-1h-1,8-naphthyridin-4-one Chemical compound N=1C2=NC(C)=CC=C2C(O)=CC=1C1=CC=CO1 INGWEZCOABYORO-UHFFFAOYSA-N 0.000 description 1
- HBEYLIJCIQABLJ-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;calcium Chemical compound [Ca].[Ca].OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O HBEYLIJCIQABLJ-UHFFFAOYSA-N 0.000 description 1
- 241000269333 Caudata Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- CIWBSHSKHKDKBQ-DUZGATOHSA-N D-isoascorbic acid Chemical compound OC[C@@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-DUZGATOHSA-N 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229920006328 Styrofoam Polymers 0.000 description 1
- GKHOLUJNLGYFHA-UHFFFAOYSA-N [Na].CC(C)=O Chemical compound [Na].CC(C)=O GKHOLUJNLGYFHA-UHFFFAOYSA-N 0.000 description 1
- 238000011481 absorbance measurement Methods 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 238000004378 air conditioning Methods 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 108010002255 deoxyhemoglobin Proteins 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 235000010350 erythorbic acid Nutrition 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000001046 green dye Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000013383 initial experiment Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 229940026239 isoascorbic acid Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 1
- 210000000956 olfactory bulb Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 235000012736 patent blue V Nutrition 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229940071643 prefilled syringe Drugs 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- KIWUVOGUEXMXSV-UHFFFAOYSA-N rhodanine Chemical compound O=C1CSC(=S)N1 KIWUVOGUEXMXSV-UHFFFAOYSA-N 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- XWGJFPHUCFXLBL-UHFFFAOYSA-M rongalite Chemical compound [Na+].OCS([O-])=O XWGJFPHUCFXLBL-UHFFFAOYSA-M 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- NLUFDZBOHMOBOE-UHFFFAOYSA-M sodium;2-[[4-(diethylamino)phenyl]-(4-diethylazaniumylidenecyclohexa-2,5-dien-1-ylidene)methyl]benzene-1,4-disulfonate Chemical compound [Na+].C1=CC(N(CC)CC)=CC=C1C(C=1C(=CC=C(C=1)S([O-])(=O)=O)S([O-])(=O)=O)=C1C=CC(=[N+](CC)CC)C=C1 NLUFDZBOHMOBOE-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 239000008261 styrofoam Substances 0.000 description 1
- 125000005504 styryl group Chemical group 0.000 description 1
- 229940044609 sulfur dioxide Drugs 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 229940035024 thioglycerol Drugs 0.000 description 1
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000000857 visual cortex Anatomy 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
- A61K49/0034—Indocyanine green, i.e. ICG, cardiogreen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0023—Di-or triarylmethane dye
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
- A61K49/0043—Fluorescein, used in vivo
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
- C09B67/00—Influencing the physical, e.g. the dyeing or printing properties of dyestuffs without chemical reactions, e.g. by treating with solvents grinding or grinding assistants, coating of pigments or dyes; Process features in the making of dyestuff preparations; Dyestuff preparations of a special physical nature, e.g. tablets, films
- C09B67/0071—Process features in the making of dyestuff preparations; Dehydrating agents; Dispersing agents; Dustfree compositions
Definitions
- the invention relates to voltage sensitive dyes. More particularly, the invention relates to storage stable compositions comprising voltage sensitive dyes.
- Indocyanine green for example, is a voltage sensitive dye with an absorption maxima around 805 nm (the isosbestic point of the hemoglobin/deoxyhemoglobin system) . This absorption makes it possible to monitor blood concentrations by ear densitometry. Indocyanine green has been used for determining cardiac output, hepatic function and liver blood flow. It also has been used for plasma volume measurement and for regional angiography of organs including the eyes, kidneys and lungs (Gennaro, A. R. , Ed Remington's Pharmaceutical Sciences Easton, PA: Mack Publishing Company, 1990, 1279. Indocyanine green, in vivo, is readily bound by plasma proteins and remains in the blood stream through one circulation of the heart and lungs.
- Indocyanine green is removed from the plasma almost exclusively by hepatic function (Osol, A.; Pratt, R. The United States Dispensatory Philadelphia, Toronto: J. B. Lippincott Company, 1973, 615) .
- indocyanine green pharmokinetics in the rabbit and relevant studies of its stability and purity, Heintz, R. ; Svensson, C.K.; Stoeckel, K. ; Powers, G. J. ; Lalka, D. J. Pharm. Sci. 1986, 75, 398- 402 .
- indocyanine green in methanol or bile remain stable (Tl/2 > ly) , but indocyanine green in duodenal fluid or distilled water decompose rapidly (e.g., Tl/2 3.6d and Tl/2 3.6d and Tl/2 1.4 d, respectively)
- ICG indocyanine green
- Plasma proteins inhibit decomposition from incandescent light (Light-absorbing properties, stability and spectral stabilization of indocyanine green, Landsman, M.L.J.; Kwant, G. ; Mook, G.A.; Zijlstra, W.G. J. Appl. Phvsiol . 1976, 40, 575- 583) as does protection from light (Studies on the stability of indocyanine green in serums, Nimata, H.; Yoshida, S.; Shimizu, N. ; Yoneya, M. ; Nishibe, M. ; Matsubara, R. Rinsho Kensa 1974, 18, 320-322) .
- the invention relates to stable aqueous solutions of voltage sensitive dyes. Particularly the invention relates to the proper formulation and storage conditions that provide marketable aqueous solutions of voltage sensitive dyes for use as optical imaging contrast agents.
- the invention is advantageous in allowing shipment and storage of the disclosed compositions either alone or in pre-filled syringes. Prior to this invention-, on site preparation was necessary due to the poor stability of the solutions. In addition, prior to the invention, shipment and storage of such dyes occurred only with solid forms of the dyes.
- Voltage sensitive dyes refers to those compositions that reflect a change in their fluorescence or absorbance with changes in voltage.
- Storage stable refers to a composition of the invention that decomposes at a slower rate than a voltage sensitive dye without an air protecting reagent.
- a decomposition inhibiting amount refers to that amount that renders the aqueous solutions of the invention storage stable.
- Air protecting reagents refers to any composition capable of inhibiting decomposition of the voltage sensitive dyes due to air.
- compositions of the invention have longer storage life (i.e., less decomposition) due to protection from light, and air, either separately, or in combinaticon.
- Some of the advantages of aqueous solutions of voltage sensitive dyes include the speed with which they can be used (i.e., no wait for solids to dissolve), the convenience with which they can be used (i.e., no worry about preparation for solution and whether or not all of the solids dissolved) , the safety with which they can be used (i.e., less chance of microbial and particulate contamination) , and the ease with which they can be used (i.e., less chance of getting any particulates from the stopper into the solution because the needle would only be pushed through once as opposed to twice for a reconstituted kit; no chance for similar contamination if a prefilled syringe is uses) .
- Voltage sensitive dyes for use in the present invention include Evans Blue (Aldrich) (C 34 H 24 N 6 Na 4 0 4 S 4 ) ,
- Suitable light protection measures to be used with compositions of the invention include the use of wrappings such as opaque wrappings, cardboard boxes, and styrofoam containers. It is especially advantageous to protect compositions of the invention from light that is the same as that absorbed by the compositions.
- Suitable air protection measures to be used with compositions of the invention include the use of air protecting reagents. Examples of air protecting reagent are antioxidants, gases, and surfactants.
- Suitable air protecting reagents for use with the invention include gases such as argon and nitrogen.
- gases such as argon and nitrogen.
- the use of gases involves purging a vial containing solid dye with argon or nitrogen and sealing. Then bubble a buffered solution, which contains the desired antioxidant or surfactant in the appropriate proportion, with argon or nitrogen. Add the degassed solution to the solid dye and transfer the solution to a purged vial, or syringe. A stopper will not resist air indefinitely so a sealed ampule may be preferable.
- Suitable antioxidants for use in practicing the invention include sodium sulfite, sodium metabisulfite, sodium thiosulfate, sodium formaldehyde sulfoxylate, acetone sodium metabisulfite, isoascorbic acid, thioglycerol, ascorbate, thiosorbitol, cysteine hydrochloride, sulfur dioxide, acetylcysteine, thiolactic acid, dithyiothreitol and glutathione (all available from Aldrich, Fisher and/or Fluka) .
- Surfactants and compositions that exhibit surfactant-like properties suitable for use with the invention include tweens, polysorbates (ICI or Sigma) , Pluronics
- ICI or Sigma Polyethylene glycols
- sodium carboxymethyl celluloses Surfactant and compositions with surfactant-like capabilities are believed to protect from air by associating with the organic functionalities or incorporating the organic molecule into a micelle.
- the amount of air protecting reagents for use with the invention range from about 0.01% to about 1.0% of an aqueous solution. Preferably a range from about 0.1% to about 0.25% is used.
- the amount of air protecting reagent generally depends upon the solubility of the particular air protecting reagent in aqueous solution.
- the storage stable aqueous solution of the invention be stable for at least the time period from the time of preparation (e.g., laboratory or pharmacy) until administration or use. Typica] lly this period is from about a few minutes to about a few hours.
- the storage stability is from about a full day (24 hours) to about a few weeks. Most preferably the storage stability is for about a year (12 months) or longer.
- a major advantage of voltage sensitive dyes is that time resolution is better than 1 millisecond (ms) compared to time resolution on the order of seconds for the commonly used intrinsic light signals.
- the invention is suitable for imaging in patients, typically warm blooded animals.
- a method for imaging using compositions of the invention comprises administering an imaging effective amount of a composition of the invention to a patient and then subjecting the patient to the desired imaging modality.
- Examples of preferred voltage sensitive dyes for use with the invention include Evan's Blue, Indocyanine Green, Congo Red, Fluorescein Sodium, Sulphan Blue, and Indigo Carmine.
- Examples of preferred air protecting reagents for use with the invention include Sodium Ascorbate, Glutathione, Dithiothreitol, Sodium Ascorbate, EDTA, Polysorbate 80, and Carboxymethylcellulose.
- compositions for formulating diagnostic compositions include those compositions for formulating diagnostic compositions.
- diagnostic compositions can be for enteral or parenteral administration and may include pharmaceutically acceptable buffers, electrolytes, surfactants, thixotropic agents, and the like.
- the diagnostic composition is administered in an imaging effective amount, an imaging effective amount being that amount necessary for obtaining the desired image.
- Diagnostic compositions contain an effective amount of the compositions of the invention along with conventional pharmaceutical carriers and excipients appropriate for the type of administration contemplated.
- parenteral formulations advantageolusly contain a sterile aqueous solution or suspension of from about 0.05 to 1.0M of a composition according to the invention.
- Preferred parenteral formulations have a concentration of about 0.1M to about 0.5M.
- Such solutions also may contain pharmaceutically acceptable buffers and, optionally, electrolytes such as sodium chloride.
- Parenteral compositions may be injected directly or mixed with a large volume parenteral composition for systemic administration.
- Formulations for enteral administration may vary widely, as is well-known in the art. In general, such formulations are liquids which include an effective amount of a composition of the invention in aqueous solution or suspension. Such enteral compositions may optionally include buffers, surfactants, thixotropic agents, and the like.
- Compositions for oral administration may also contain flavoring agents and other ingredients for enhancing their organoleptic qualities.
- the diagnostic compositions are administered in doses effective to achieve the desired enhancement of the image.
- doses may vary, depending upon the particular composition employed, the organs or tissues which are the subject of the imaging procedure, the imaging procedure, the imaging equipment being used, and so forth.
- parenteral dosages will range from about 0.01 to about 1.
- OMMol of composition of the invention per kg of patient body weight .
- Preferred parenteral dosages range from about 0.05 to about 0.5MMol per kg of patient body weight.
- Enteral dosages generally range from about 0.5 to about 100 MMol, preferably from about 1.0 to about 10 MMol per kg of patient body weight.
- compositions of the invention are used in the conventional manner.
- the compositions may be administered to a patient, typically a warm-blodded animal, either systemically or locally to the organ or tissue to be imaged, and the patient then subjected to the imaging procedure.
- ICG Indocyanine green
- EDTA dicalcium ethylenediaminetetraacetic acid
- UV-Visible spectra were recorded on a Cary 3E spectrophotometer over a region of 600 to 900 nm.
- the phosphate buffer was prepared by dissolving 0.2975 g of NaH 2 P0 4 H 2 0 and 1.0813 g of Na 2 HP0 4 in 250 mL of deionized water. The pH of the buffer was 7.39.
- Example 2
- Example 2 Analogous solutions to those in Example 1 were used, however they were not irradiated. Instead, the solutions were heated in a hot water bath at 50-53C. In the air free solution, the absorbance decreased from -1.1 to 1.05 after 90 min.; the solution with air showed a decrease in absorbance from 1.6 to 1.3 over the same time frame. Comparing these results to those in Example 2 indicates that it is light, not heat, that is the major factor affecting the rate of decomposition of the dye.
- Example 5 A solution analogous to that used in Example 5 was used, except this time, a spatula tip of solid sodium ascorbate was added also. After 60 min., the absorbance of an air-containing solution decreased from 1.0 to 0.7.
- Example 5 The same solution as in Example 5 was prepared, however 3 mL of a 0.0002 M solution of sodium ascorbate (4% of ICG concentration) was added, also. After 60 minutes, a degassed solution showed a decrease in absorbance from 1.0 to 0.15. Comparing this to the result in Example 5, the presence of 0.0002 M ascorbate does not retard the decomposition of the ICG.
- a heaping scoop of sodium bisulfite was added to 3 mL of a solution containing 1.25 mg of ICG in 250 mL of phosphate buffer.
- the initial absorbance is -0.3, however, after only 15 minutes, the absorbance is 0.0.
- the bisulfite is destroying the dye.
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU67076/94A AU6707694A (en) | 1993-04-20 | 1994-04-19 | Stabilization of voltage sensitive dyes |
JP6523530A JPH08509260A (ja) | 1993-04-20 | 1994-04-19 | 電圧感受性染料の安定化 |
EP94914830A EP0695138A4 (fr) | 1993-04-20 | 1994-04-19 | Stabilisation de colorants sensibles a la tension |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4993693A | 1993-04-20 | 1993-04-20 | |
US08/049,936 | 1993-04-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1994023646A1 true WO1994023646A1 (fr) | 1994-10-27 |
Family
ID=21962548
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1994/004267 WO1994023646A1 (fr) | 1993-04-20 | 1994-04-19 | Stabilisation de colorants sensibles a la tension |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0695138A4 (fr) |
JP (1) | JPH08509260A (fr) |
AU (1) | AU6707694A (fr) |
MX (1) | MXPA94002884A (fr) |
WO (1) | WO1994023646A1 (fr) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999013916A2 (fr) * | 1997-09-18 | 1999-03-25 | Nycomed Imaging As | Procedes et compositions pour l'imagerie medicale |
EP0946203A1 (fr) * | 1996-05-13 | 1999-10-06 | Mallinckrodt, Inc. | Colorants fonctionnels tricycliques pour l'amelioration du constraste en imagerie optique |
WO2003057259A2 (fr) * | 2001-12-27 | 2003-07-17 | Akorn, Inc. | Compositions de vert d'indocyanine et procedes d'utilisation correspondants |
WO2015095344A1 (fr) * | 2013-12-17 | 2015-06-25 | University Of Chicago | Composition sensible aux variations de tension et son procédé d'utilisation |
WO2022026628A1 (fr) * | 2020-07-31 | 2022-02-03 | Cao Group, Inc | Solutions vertes d'indocyanine stables au stockage et leurs procédés de fabrication |
WO2022194734A1 (fr) * | 2021-03-17 | 2022-09-22 | Provepharm Life Solutions | Formulations stables de vert d'indocyanine |
WO2022194731A1 (fr) | 2021-03-17 | 2022-09-22 | Provepharm Life Solutions | Formulations stables de vert d'indocyanine |
WO2022194733A2 (fr) | 2021-03-17 | 2022-09-22 | Provepharm Life Solutions | Formulations stables de vert d'indocyanine |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4369250A (en) * | 1981-07-31 | 1983-01-18 | Sherwood Medical Industries Inc. | Fatty acid determination |
US4478818A (en) * | 1982-12-27 | 1984-10-23 | Alza Corporation | Ocular preparation housing steroid in two different therapeutic forms |
US4526701A (en) * | 1981-08-31 | 1985-07-02 | Lever Brothers Company | Dye stabilized detergent compositions |
US5266302A (en) * | 1990-10-03 | 1993-11-30 | Peyman Gholam A | Method of performing angiography |
-
1994
- 1994-04-19 AU AU67076/94A patent/AU6707694A/en not_active Abandoned
- 1994-04-19 WO PCT/US1994/004267 patent/WO1994023646A1/fr not_active Application Discontinuation
- 1994-04-19 JP JP6523530A patent/JPH08509260A/ja active Pending
- 1994-04-19 EP EP94914830A patent/EP0695138A4/fr not_active Withdrawn
- 1994-04-20 MX MX9402884A patent/MXPA94002884A/es unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4369250A (en) * | 1981-07-31 | 1983-01-18 | Sherwood Medical Industries Inc. | Fatty acid determination |
US4526701A (en) * | 1981-08-31 | 1985-07-02 | Lever Brothers Company | Dye stabilized detergent compositions |
US4478818A (en) * | 1982-12-27 | 1984-10-23 | Alza Corporation | Ocular preparation housing steroid in two different therapeutic forms |
US5266302A (en) * | 1990-10-03 | 1993-11-30 | Peyman Gholam A | Method of performing angiography |
Non-Patent Citations (4)
Title |
---|
Journal of Applied Physiology, Vol. 29, No. 2, issued August 1970 (USA), J. GATHJE et al., "Stability Studies on Indocyanine Green Dye", see pages 181-185, especially page 181. * |
Journal of Applied Physiology, Vol. 40, No. 4, issued April 1976 (USA), M.L.J. LANDSMAN et al., "Light-Absorbing Properties, Stability, and Spectral Stabilization of Indocyanine Green", see pages 575-582, especially page 582. * |
Journal of Pharmaceutical Sciences, Vol. 75, No. 4, issued April 1986, R. HEINTZ et al., "Indocyanine Green: Pharmacokinetics in the Rabbit and Relevant Studies of Its Stability and Purity", see pages 398-402, especially page 398. * |
See also references of EP0695138A4 * |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0946203A1 (fr) * | 1996-05-13 | 1999-10-06 | Mallinckrodt, Inc. | Colorants fonctionnels tricycliques pour l'amelioration du constraste en imagerie optique |
EP0946203A4 (fr) * | 1996-05-13 | 2000-03-29 | Mallinckrodt Inc | Colorants fonctionnels tricycliques pour l'amelioration du constraste en imagerie optique |
WO1999013916A2 (fr) * | 1997-09-18 | 1999-03-25 | Nycomed Imaging As | Procedes et compositions pour l'imagerie medicale |
WO1999013916A3 (fr) * | 1997-09-18 | 2001-12-20 | Nycomed Imaging As | Procedes et compositions pour l'imagerie medicale |
WO2003057259A2 (fr) * | 2001-12-27 | 2003-07-17 | Akorn, Inc. | Compositions de vert d'indocyanine et procedes d'utilisation correspondants |
WO2003057259A3 (fr) * | 2001-12-27 | 2003-09-18 | Akorn Inc | Compositions de vert d'indocyanine et procedes d'utilisation correspondants |
WO2015095344A1 (fr) * | 2013-12-17 | 2015-06-25 | University Of Chicago | Composition sensible aux variations de tension et son procédé d'utilisation |
WO2022026628A1 (fr) * | 2020-07-31 | 2022-02-03 | Cao Group, Inc | Solutions vertes d'indocyanine stables au stockage et leurs procédés de fabrication |
WO2022194734A1 (fr) * | 2021-03-17 | 2022-09-22 | Provepharm Life Solutions | Formulations stables de vert d'indocyanine |
WO2022194731A1 (fr) | 2021-03-17 | 2022-09-22 | Provepharm Life Solutions | Formulations stables de vert d'indocyanine |
WO2022194733A2 (fr) | 2021-03-17 | 2022-09-22 | Provepharm Life Solutions | Formulations stables de vert d'indocyanine |
WO2022194733A3 (fr) * | 2021-03-17 | 2022-11-10 | Provepharm Life Solutions | Formulations stables de vert d'indocyanine |
Also Published As
Publication number | Publication date |
---|---|
EP0695138A1 (fr) | 1996-02-07 |
EP0695138A4 (fr) | 1998-09-02 |
MXPA94002884A (es) | 2002-06-18 |
JPH08509260A (ja) | 1996-10-01 |
AU6707694A (en) | 1994-11-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3212997B2 (ja) | 酸素濃度の測定に使用する蛍光プローブ | |
ES2235297T3 (es) | Agente de diagnostico para la funcion hepatica. | |
US20090137902A1 (en) | Intraoperative imaging methods | |
ES2331671T3 (es) | Bioconjugados no covalentes utiles para diagnostico y terapia. | |
EP0695138A1 (fr) | Stabilisation de colorants sensibles a la tension | |
CA2250485C (fr) | Agent de diagnostic du diabete | |
Fuke et al. | Postmortem diffusion of ingested and aspirated paint thinner | |
Kotelanski et al. | Effect of ethanol on sulfobromophthalein and indocyanine green metabolism in isolated perfused rat liver | |
Namykin et al. | Intravital molecular tagging velocimetry of cerebral blood flow using Evans Blue | |
Udagawa et al. | Aberrant porphyrin metabolism in hepatocellular carcinoma | |
Hazinedaroglu et al. | N‐Acetylcysteine in intestinal reperfusion injury: an experimental study in rats | |
JP3949184B2 (ja) | 塩酸アンブロキソール水性液剤 | |
US6416736B1 (en) | Use of hemoglobin derivatives for determining plasma and/or blood volume | |
CN117062597A (zh) | 稳定的吲哚菁绿制剂 | |
JP2024510501A (ja) | インドシアニングリーンの安定な処方物 | |
JP2024510302A (ja) | インドシアニングリーンの安定な処方物 | |
Räsänen et al. | Fatal familial steatosis of the liver and kidney in two siblings | |
WO2006079091A1 (fr) | Procedes pour conferer une stabilite a long terme a des colorants optiques biocompatibles et liquides organiques | |
Lee et al. | Cyanide-related changes in cerebral O2 delivery and metabolism in fluorocarbon-circulated rats | |
JPH11209309A (ja) | 糖尿病診断剤 | |
Wienert et al. | Methodology and application of fluorescence techniques in dermatology | |
JP2022155560A (ja) | スガマデクスの光分解抑制方法 | |
Calderon et al. | Chronic idiopathic jaundice: a case report | |
MacMahon et al. | Protein-Losing Enteropathy Possible Due to Filariasis | |
Staubus | Fundamentals of saturation kinetics--application to iopanic acid in the dog |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BR CA CZ FI HU JP KR NO PL SK |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1994914830 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1994914830 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1994914830 Country of ref document: EP |